Dec. 31, 2020, 6:46 a.m. EST

These Two Drug Stocks are On Sale: Pfizer and GlaxoSmithKline

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

Dec 31, 2020 (Baystreet.ca via COMTEX) -- The market's fleeting buying interest in drug manufacturers led to Pfizer /zigman2/quotes/202877789/composite PFE +0.26% and GlaxoSmithKline /zigman2/quotes/209463850/composite GSK -0.74% falling sharply. Pfizer's under-performance is especially notable. After benefitting from positive media coverage for its partnership with BioNtech /zigman2/quotes/214419716/composite BNTX +4.48% , markets sold shares of both companies.

What happened?

The buying and selling cycle in coronavirus vaccine companies continued throughout the year. BNTX and Moderna /zigman2/quotes/205619834/composite MRNA -3.17% tended to under-perform for months after posting positive news. And as markets anticipated strong sales for the vaccine, buyers would buy those vaccine suppliers.

Investors prefer to look at Pfizer's overall business growth prospects and its suitability as an income investment instead. Similarly, GSK stock pays a healthy dividend yield, too. But as markets chase high-flying vaccine stocks that may offer bigger returns in the near term, such stocks will underperform.

Patient income investors should accumulate GSK and PFE stock at current levels. GSK is working with Vir Biotechnology /zigman2/quotes/214486077/composite VIR +2.63% to evaluate VIR-7831. This is a monoclonal antibody that has been shown to neutralize the virus in vivo and in vitro. If the companies post positive clinical results, buyers may take another look at GSK, especially when the stock is trading at a discount.

COMTEX_377048396/2559/2020-12-31T06:45:38

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 39.03
+0.10 +0.26%
Volume: 26.46M
April 20, 2021 4:02p
P/E Ratio
22.82
Dividend Yield
4.00%
Market Cap
$209.74 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 37.70
-0.28 -0.74%
Volume: 5.50M
April 20, 2021 4:00p
P/E Ratio
12.96
Dividend Yield
5.30%
Market Cap
$92.89 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 156.18
+6.70 +4.48%
Volume: 3.22M
April 20, 2021 4:00p
P/E Ratio
1,490
Dividend Yield
N/A
Market Cap
$33.99 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 156.78
-5.13 -3.17%
Volume: 7.15M
April 20, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$63.98 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 48.46
+1.24 +2.63%
Volume: 1.06M
April 20, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.76 billion
Rev. per Employee
$233,541
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.